Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

被引:0
作者
J. M. M. Evans
S. A. Ogston
A. Emslie-Smith
A. D. Morris
机构
[1] University of Dundee Medical School,Section of Public Health, Division of Community Health Sciences
[2] The Mill Practice,Division of Medicine and Therapeutics
[3] University of Dundee Medical School,undefined
来源
Diabetologia | 2006年 / 49卷
关键词
Cardiovascular risk; Metformin; Sulfonylureas;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 30 条
[1]  
Johnson JA(2002)Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 25 2244-2248
[2]  
Simpson SH(1972)A summary of criticisms of the findings of the University Group Diabetes Program Diabetes 21 976-979
[3]  
Majumdar SR(1996)Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 39 503-514
[4]  
Toth EL(1998)Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
[5]  
Seltzer HS(1998)Some answers, more controversy, from UKPDS Lancet 352 832-833
[6]  
Leibowitz G(1998)Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854-865
[7]  
Cerasi E(2000)Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study Diabetologia 43 558-560
[8]  
Nathan DM(2001)Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7 year follow-up Clin Cardiol 24 151-158
[9]  
Olsson J(2004)Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study Diabetes Metab Res Rev 20 239-245
[10]  
Lindberg G(1995)The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance Pharm Med 9 177-184